DK0858467T3 - Materialer og fremgangsmåder angående identifikationen og sekventeringen af BRCA2 cancerfölsomhedsgen og anvendelser deraf - Google Patents

Materialer og fremgangsmåder angående identifikationen og sekventeringen af BRCA2 cancerfölsomhedsgen og anvendelser deraf

Info

Publication number
DK0858467T3
DK0858467T3 DK96939218T DK96939218T DK0858467T3 DK 0858467 T3 DK0858467 T3 DK 0858467T3 DK 96939218 T DK96939218 T DK 96939218T DK 96939218 T DK96939218 T DK 96939218T DK 0858467 T3 DK0858467 T3 DK 0858467T3
Authority
DK
Denmark
Prior art keywords
brca2
sequencing
identification
materials
methods
Prior art date
Application number
DK96939218T
Other languages
English (en)
Inventor
Phillip Andrew Futreal
Richard Francis Wooster
Alan Ashworth
Michael Rudolf Stratton
Original Assignee
Cancer Res Campaign Tech
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0858467(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9523959.6A external-priority patent/GB9523959D0/en
Priority claimed from GBGB9525555.0A external-priority patent/GB9525555D0/en
Priority claimed from GBGB9617961.9A external-priority patent/GB9617961D0/en
Application filed by Cancer Res Campaign Tech, Univ Duke filed Critical Cancer Res Campaign Tech
Application granted granted Critical
Publication of DK0858467T3 publication Critical patent/DK0858467T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DK96939218T 1995-11-23 1996-11-25 Materialer og fremgangsmåder angående identifikationen og sekventeringen af BRCA2 cancerfölsomhedsgen og anvendelser deraf DK0858467T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9523959.6A GB9523959D0 (en) 1995-11-23 1995-11-23 Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of cancer
GBGB9525555.0A GB9525555D0 (en) 1995-12-14 1995-12-14 Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of cancer
GBGB9617961.9A GB9617961D0 (en) 1996-08-28 1996-08-28 Materials and methods relating to the diagnosis and prophylactic and therapeuti treatment of cancer
PCT/GB1996/002904 WO1997019110A1 (en) 1995-11-23 1996-11-25 Materials and methods relating to the identification and sequencing of the brca2 cancer susceptibility gene and uses thereof

Publications (1)

Publication Number Publication Date
DK0858467T3 true DK0858467T3 (da) 2004-06-14

Family

ID=27267991

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96939218T DK0858467T3 (da) 1995-11-23 1996-11-25 Materialer og fremgangsmåder angående identifikationen og sekventeringen af BRCA2 cancerfölsomhedsgen og anvendelser deraf

Country Status (10)

Country Link
US (1) US6045997A (da)
EP (1) EP0858467B1 (da)
JP (1) JP2001507563A (da)
AT (1) ATE259378T1 (da)
AU (1) AU707636C (da)
CA (1) CA2238010A1 (da)
DE (1) DE69631540T2 (da)
DK (1) DK0858467T3 (da)
ES (1) ES2217328T3 (da)
WO (1) WO1997019110A1 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
CA2239733C (en) * 1995-12-18 2001-04-03 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
AU773601B2 (en) * 1995-12-18 2004-05-27 Endorecherche Inc. Chromosome 13-linked breast cancer susceptibility gene
US5837492A (en) 1995-12-18 1998-11-17 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
US20030022184A1 (en) * 1996-02-12 2003-01-30 Oncormed. Inc. Coding sequences of the human BRCA1 gene
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
DE69830395T2 (de) * 1997-03-20 2006-01-26 Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara Iterative resequenzierung
US20140302494A9 (en) * 1997-08-15 2014-10-09 Myriad Genetics, Incorporated Method of analyzing a brca2 gene in a human subject
WO1999009164A1 (en) * 1997-08-15 1999-02-25 Oncormed, Inc. Coding sequence haplotypes of the human brca2 gene
US20090269814A1 (en) * 1998-05-22 2009-10-29 Murphy Patricia D Method of Analyzing a BRCA2 Gene in a Human Subject
US6207370B1 (en) 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
US6686163B2 (en) 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
US6562958B1 (en) * 1998-06-09 2003-05-13 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
DE60025704T2 (de) * 1999-02-24 2006-09-07 Juan Saus Das goodpasture-antigen bindende protein
EP1287162A2 (en) 1999-10-21 2003-03-05 Case Western Reserve University Gene expression profiling of inflammatory bowel disease
AT409381B (de) * 2000-03-03 2002-07-25 Gloessl Josef Dr Xylosyltransferase-gen
US6727353B2 (en) * 2000-04-14 2004-04-27 Icagen, Inc. Nucleic acid encoding Kv10.1, a voltage-gated potassium channel from human brain
EP1953243B1 (en) 2000-06-15 2012-12-26 Novartis Vaccines and Diagnostics, Inc. Polynucleotides related to colon cancer
WO2002004628A2 (en) 2000-07-06 2002-01-17 Genvec, Inc. Method of identifying a binding partner of a gene product
DE50015173D1 (de) 2000-07-13 2008-07-03 Ct Concept Technologie Ag Verfahren und vorrichtung zur zustandsabhängigen regelung des transienten verhaltens von leistungshalbleiterschaltern
US20030175749A1 (en) * 2001-12-08 2003-09-18 Jong-Yoon Chun Annealing control primer and its uses
WO2003104429A2 (en) * 2002-06-10 2003-12-18 Idec Pharmaceuticals Corporation Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
US7461048B2 (en) * 2003-07-21 2008-12-02 Aureon Laboratories, Inc. Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
US7892823B2 (en) * 2007-02-06 2011-02-22 Geneprotech, Inc. Methods and systems for high homologous recombination (“HR”) targeting efficiency
US8759089B2 (en) * 2007-02-06 2014-06-24 Geneprotech, Inc. Methods and systems for high homologous recombination (“HR”) targeting efficiency
US20130058979A1 (en) * 2009-11-30 2013-03-07 Agency For Science, Technology And Research Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination
ES2896404T3 (es) 2014-04-04 2022-02-24 Crown Bioscience Inc Taicang Métodos para determinar la capacidad de respuesta a inhibidores de MEK/ERK
US11773449B2 (en) 2017-09-01 2023-10-03 The Hospital For Sick Children Profiling and treatment of hypermutant cancer
CN116179710B (zh) * 2023-03-14 2023-11-24 成都诺森医学检验有限公司 基于高通量测序平台的brca1/2基因突变检测的引物组、文库构建与环化方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393502B1 (en) * 1989-04-19 1995-12-27 F. Hoffmann-La Roche Ag Soluble interferon-gamma receptors and methods for their production
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
EP0739894A4 (en) * 1994-01-14 1997-03-26 Taisho Pharmaceutical Co Ltd THIAZOLINE DERIVATIVE
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer

Also Published As

Publication number Publication date
DE69631540T2 (de) 2005-01-27
EP0858467B1 (en) 2004-02-11
AU7635096A (en) 1997-06-11
AU707636C (en) 2003-01-16
WO1997019110A1 (en) 1997-05-29
ATE259378T1 (de) 2004-02-15
AU707636B2 (en) 1999-07-15
US6045997A (en) 2000-04-04
CA2238010A1 (en) 1997-05-29
DE69631540D1 (de) 2004-03-18
ES2217328T3 (es) 2004-11-01
EP0858467A1 (en) 1998-08-19
JP2001507563A (ja) 2001-06-12

Similar Documents

Publication Publication Date Title
DK0858467T3 (da) Materialer og fremgangsmåder angående identifikationen og sekventeringen af BRCA2 cancerfölsomhedsgen og anvendelser deraf
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
DE69707985D1 (de) Kodierende sequenzen des menschlichen brca1-gens
DK0991421T3 (da) Påvisning og modulering af IAP'er og NAIP i forbindelse med diagnose og behandling af proliferativ sygdom
ATE418563T1 (de) Nik proteine, nukleinsäure sowie verfahren
PT917571E (pt) Gene relacionado com agouti
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
ATE299180T1 (de) Intrazellulare domäne des her-2/neu proteins, für die prevention oder behandlung von bösartigen tumoren
GR3019849T3 (en) Acute pancreatitis associated protein and means for the diagnosis of acute pancreatitis
NZ270659A (en) Mammalian protein which binds to a gst-fkbp-rapamycin complex, dna therefor and diagnostic compositions
HUP9900018A1 (hu) Cirkuláris DNS-molekula feltételes replikációs origóval, eljárás előállítására és génterápiában való felhasználására
WO2002088750A3 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
DE69523586D1 (de) Verfahren zum screening für die erkrankung crohn durch die verwendung von tnf-mikrosatelliten allelen
MX9805299A (es) Novedosos polinucleotidos panc1a y panc1b asociados con cancer pancreatico.
ATE329055T1 (de) Methode zur erstellung von genexpressionsprofilen
HUP0203724A2 (hu) Humán heparanázzal rokon polipeptidek és nukleinsavak
EP0960128A4 (en) Gene product overexpressed in cancer cells
ATE382637T1 (de) Rezeptor-tyrosine-kinase gene
DK0941341T3 (da) Nukleotidsekvens, der koder for en flavinmonooxygenase, det tilsvarende protein og deres anvendelser inden for diagnostik og terapi
BR0012301A (pt) Inibidores de crescimento de células epiteliais
WO2004048548A3 (en) Methods for identifying risk of breast cancer and treatments thereof
ATE542900T1 (de) Icbp90-polypeptide, polypeptidfragmente davon, die dafür kodierenden polynukleotide, und ihre verwendung zur behandlung und diagnose von krebs
UA66753C2 (en) Immunostimulator and method for its production
TH43183A (th) " ยีนสำหรับการสังเคราะห์สารต่อต้านเชื้อสาเหตุของโรค "